时间对事件瘤学随机试验的替代治疗效果测量方法
1Roswell Park Comprehensive Cancer Center, Department of Biostatistics and Bioinformatics, Elm and Carlton Streets, Buffalo, NY 14623, USA.
Cancers
|December 11, 2025
概括
一个新的终点,单变马丁加尔残留值 (UMR),提供了一种无假设的方法来分析瘤学试验生存数据. 这种方法提供了强大而准确的推断,在复杂的场景中优于传统的生存分析.
科学领域:
- 生物统计学 生物统计学
- 临床试验 临床试验
- 生存分析的分析.
背景情况:
- 像总生存率 (OS) 这样的时间到事件终点在III期瘤学试验中至关重要.
- 目前的方法 (Cox模型,日志级测试) 依赖于比例危险和大样本假设.
- 这些标准方法可能是不可靠的,有严重的审查或不成比例的危险.
研究的目的:
- 引入单变 Martingale 余数 (UMR) 作为一个新的终点和总结度量.
- 开发一个精确的推理框架,使用UMR的随机化测试.
- 在瘤学试验中为传统的生存分析提供强大的替代方案.
主要方法:
- UMR量化了每个受试者的观察和预期事件之间的差异.
- 每只手臂的平均UMR提供了过量事件的绝对衡量标准.
- 一个基于随机化的测试框架计算了精确的p值,绕过了比例危险和非对称假设.
主要成果:
- 在沉重的审查和不成比例的危险下,UMR提供了稳定和可解释的摘要.
- 基于UMR的随机化测试保持了I型错误控制.
- 当违反比例危险时,UMR测试比日志等级测试具有竞争力或更强大.
结论:
- UMR提供了一个直观的,没有假设的治疗效果总结.
- UMR支持准确的推断,这对于可靠的临床试验结果至关重要.
- UMR是第三阶段瘤学试验的实用和强大的替代方案,特别是在复杂的生存情况下.
相关概念视频
Comparing the Survival Analysis of Two or More Groups
533
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
533
Cancer Survival Analysis
629
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
629
Kaplan-Meier Approach
536
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
536
Hazard Ratio
549
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
549
The Mantel-Cox Log-Rank Test
965
The Mantel-Cox log-rank test is a widely used statistical method for comparing the survival distributions of two groups. It tests whether a statistically significant difference exists in survival times between the groups without assuming a specific distribution for the survival data, making it a non-parametric test. This flexibility makes the log-rank test particularly valuable in medical research and other fields where the timing of an event, such as death or disease recurrence, is of...
965
Actuarial Approach
276
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
276


